{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.57","value":"80.18"},{"groupId":"OG001","spread":"22.01","value":"82.88"},{"groupId":"OG002","spread":"17.61","value":"79.09"},{"groupId":"OG003","spread":"7.78","value":"75.80"},{"groupId":"OG004","spread":"41.17","value":"95.37"},{"groupId":"OG005","spread":"21.56","value":"80.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.05","value":"-2.65"},{"groupId":"OG001","spread":"10.29","value":"-5.30"},{"groupId":"OG002","spread":"8.31","value":"2.09"},{"groupId":"OG003","spread":"8.25","value":"-1.22"},{"groupId":"OG004","spread":"29.44","value":"-8.51"},{"groupId":"OG005","spread":"12.89","value":"-0.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.92","value":"-4.42"},{"groupId":"OG001","spread":"11.32","value":"-4.60"},{"groupId":"OG002","spread":"12.69","value":"-1.85"},{"groupId":"OG003","spread":"27.29","value":"3.65"},{"groupId":"OG004","spread":"130.24","value":"29.39"},{"groupId":"OG005","spread":"17.59","value":"0.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.81","value":"-3.80"},{"groupId":"OG001","spread":"11.98","value":"-7.74"},{"groupId":"OG002","spread":"9.66","value":"-1.44"},{"groupId":"OG003","spread":"10.05","value":"-10.39"},{"groupId":"OG004","spread":"36.71","value":"-17.17"},{"groupId":"OG005","spread":"9.84","value":"-4.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"31"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.97","value":"-6.45"},{"groupId":"OG001","spread":"12.70","value":"-11.09"},{"groupId":"OG002","spread":"10.95","value":"1.85"},{"groupId":"OG003","spread":"8.20","value":"-12.27"},{"groupId":"OG004","spread":"37.86","value":"-20.08"},{"groupId":"OG005","spread":"9.36","value":"-4.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"31"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.29","value":"-6.28"},{"groupId":"OG001","spread":"9.05","value":"-13.26"},{"groupId":"OG002","spread":"13.78","value":"4.88"},{"groupId":"OG003","spread":"6.90","value":"-12.38"},{"groupId":"OG004","spread":"39.17","value":"-21.85"},{"groupId":"OG005","spread":"18.08","value":"-1.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"31"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG000","title":"RRMM Dose-evaluation: Carfilzomib 56 mg/m²"},{"description":"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG001","title":"RRMM Dose-evaluation: Carfilzomib 70 mg/m²"},{"description":"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG002","title":"RRMM Dose-expansion: Carfilzomib 70 mg/m²"},{"description":"Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG003","title":"NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²"},{"description":"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG004","title":"NDMM Dose-expansion: Carfilzomib 70 mg/m²"},{"description":"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG005","title":"NDMM Dose-expansion: Carfilzomib 56 mg/m²"}],"paramType":"MEAN","populationDescription":"Participants in the safety analysis set with available data at each time point.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15","title":"Change From Baseline in Creatinine","type":"PRIMARY","unitOfMeasure":"µmol/L"}